Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
Journal of Thrombosis and Haemostasis · 2023-03 · 21 (3) · 559-572
DOI: 10.1016/j.jtha.2022.11.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-03. Verfasst von Linus A Völker und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Colo…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Single-Domain Antibodies, Purpura, Thrombocytopenic, Idiopathic, Thrombosis. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Bundesministerium für Bildung und Forschung, Shire, CSL Behring.
Abstract (Originalsprache)
BACKGROUND: The von Willebrand factor-directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety. OBJECTIVES: This study aims to address open questions regarding patient selection, tailoring of therapy duration, obstacles in prescribing caplacizumab in iTTP, effect on adjunct treatment, and outcomes in the real-world setting. METHODS: We report retrospective, observational cohorts of 113 iTTP episodes treated with caplacizumab and 119 historical control episodes treated without caplacizumab. We aggregated data from the caplacizumab phase II/III trials and real-world data from France, the United Kingdom, Germany, and Austria (846 episodes, 396 treated with caplacizumab, and 450 historical controls). RESULTS: Caplacizumab was efficacious in iTTP, independent of the timing of therapy initiation, but curtailed the time of active iTTP only when used in the first-line therapy within 72 hours after diagnosis and until at least partial ADAMTS13-activity remission. Aggregated data from multiple study populations showed that caplacizumab use resulted in significant absolute risk reduction of 2.87% for iTTP-related mortality (number needed to treat 35) and a relative risk reduction of 59%. CONCLUSION: Caplacizumab should be used in first line and until ADAMTS13-remission, lowers iTTP-related mortality and refractoriness, and decreases the number of daily plasma exchange and hospital stay. This trial is registered at www. CLINICALTRIALS: gov as #NCT04985318.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Cologne Cluster of Excellence on Cellular Stres…
- Department of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany.
- Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany.
- Department of Nephrology and Hypertension, University Hospital Schleswig-Holstein, Kiel, Germany.
- Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Förderung
- Bundesministerium für Bildung und Forschung
- Shire
- CSL Behring
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Völker, L. A., Kaufeld, J., Balduin, G., Merkel, L., Kühne, L., Eichenauer, D. A., Osterholt, T., Hägele, H., Kann, M., Grundmann, F., Kolbrink, B., Schulte, K., Gäckler, A., Kribben, A., Boss, K., Potthoff, S. A., Rump, L. C., Schmidt, T., Mühlfeld, A. S., …, & German TTP-Study Group (2023). Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 21(3), 559-572. https://doi.org/10.1016/j.jtha.2022.11.010
Vancouver
Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, et al. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2023;21(3):559-572. doi:10.1016/j.jtha.2022.11.010
BibTeX
@article{Vlker2023,
author = {Völker, Linus A and Kaufeld, Jessica and Balduin, Gesa and Merkel, Lena and Kühne, Lucas and Eichenauer, Dennis A and Osterholt, Thomas and Hägele, Holger and Kann, Martin and Grundmann, Franziska and Kolbrink, Benedikt and Schulte, Kevin and Gäckler, Anja and Kribben, Andreas and Boss, Kristina and Potthoff, Sebastian A and Rump, Lars C and Schmidt, Tilman and Mühlfeld, Anja S and Schulmann, Karsten and Hermann, Matthias and Gaedeke, Jens and Sauerland, Kristin and Bramstedt, Jörn and Hinkel, Ulrich P and Miesbach, Wolfgang and Bauer, Frederic and Westhoff, Timm H and Bruck, Heike and Buxhofer-Ausch, Veronika and Müller, Tobias J and Wendt, Ralph and Harth, Ana and Schreiber, Adrian and Seelow, Evelyn and Tölle, Markus and Gohlisch, Christopher and Bieringer, Markus and Geuther, Gesa and Jabs, Wolfram J and Fischereder, Michael and von Bergwelt-Baildon, Anke and Schönermarck, Ulf and Knoebl, Paul and Menne, Jan and Brinkkoetter, Paul T and German TTP-Study Group, German TTP-Study Group},
title = {Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
volume = {21},
number = {3},
pages = {559--572},
doi = {10.1016/j.jtha.2022.11.010}
}
EUVIMED